SARS-CoV-2 Associated Thrombotic Coagulopathy

Ajaz Bulbul and Karl Koessler-Streiker

Department of Hematology and Oncology, Artesia General Hospital, Mexico Department of Hematology and Oncology, Texas Tech University Health Sciences Center School of Medicine, USA Department of Internal Medicine, The University of New Mexico, Mexico Burrell College of Osteopathic Medicine, Mexico

^*Correspondance to: Ajaz Bulbul 

 PDF  Full Text Review Article | Open Access

Abstract:

The most common patterns of hematological complications in a critically affected COVID-19 patient are a subject of great interest currently. As more data comes to fray, we are beginning to understand the underpinnings of the myriad hematological effects of COVID-19 associated multiorgan affects. The hematological issues concerning COVID-19 include thrombosis (COVID Associated Coagulopathy: CAC), PIC (Pulmonary Intravascular Coagulopathy)/DIC, thrombocytopenia and leucopenia (lymphocytopenia). COVID-19 patients like all critically ill have variety of potential risk factors driving coagulopathy, including systemic infection, immobilization, mechanical respiratory ventilation, central catheterization [1]. It is this interplay of risk factors that makes management of COVID-19 associated coagulopathy complicated to understand and manage.

Keywords:

Cite the Article:

Bulbul A, Koessler-Streiker K. SARS-CoV-2 Associated Thrombotic Coagulopathy. Clin Oncol. 2020; 5: 1726.